March 2015
Volume 2

2nd  Edition of Time To Chill

This is the 2nd of many newsletters to come. This is a great way to connect with everyone near and far and to stay up to date on the "happenings" with FN3. In each edition we will have a feature story, this may be about something exciting with the network, a great family story, an outstanding nurse or physician being recognized for excellence, or simply a note updating on the current status of the study. Please feel free to send in requests and stories to share to Nicole Copenhaver at ncopenhaver@ufl.edu.

 

---

FN3 welcomes Kim Barnette. RRT-NPS, CCRC to the network. Kim is the new Research Administrator for the division of neonatology for University of Florida Jacksonville. She has a background in respiratory therapy in a critical care setting for over 20 years with the majority of her focus in pediatrics and neonatology including transport and ECMO. Kim has been working with Dr. Mark Hudak as a Research Manager since April 2007, and has had the good fortune to have a very successful research team covering a multitude of NIH, industry and investigator driven clinical trials. She will be a great addition to the network and we are grateful to have her as part of such a "Cool" team!  

 

 

---

FN3 Developmental Follow Up

Florida Neonatal Neurologic Network is committed to caring for and following all of our patients and just recently were able to start the follow up Brain Team appointments at UFHealth Shands Gainesville. The clinic went live on March 9th and marked the start of this wonderful neurodevelopmental assessment in which we are able to collaborate with neurology and perform a Bayley III neurological exam. The patients seen in clinic are high risk infants aged 18 months to 2 years of age.

As a network FN3 is collecting very important data with the collection of serum samples. The sample data, coupled with the results from Bailey III exams, will demonstrate a correlation between serum biomarker concentrations and outcomes. These results will also strongly support FN3's theory that the concentrations of UCH-L1 and GFAP will decrease to concentrations comparable to controls over the first 24 hours of hypothermia, which allows the accuracy of predicting which infants will respond to therapeutic hypothermia. The neonates who will respond and have favorable outcomes will have lower pre-treatment GFAP and UCH-L1 concentrations than non-responders.

Pictures and updates on the Developmental Follow will be posted on the website.

---

Save The Date!!!

FN3 annual state meeting is scheduled  August 1st. 2015. You don't want to miss this. More details on location and times to come.